SMD Life Sciences
Home/Services/Custom Monoclonal Antibody
Milestone-Based Hybridoma Development • 100% Client IP

Custom Monoclonal Antibody
Development & Scale-Up Services

From antigen design and mouse immunization to high-throughput hybridoma screening and bioreactor scale-up. Engineered specifically for IVD rapid test manufacturers, high-sensitivity ELISA developers, and biopharma researchers.

4 Phases
Milestone payment structure
≥ 1:128,000
Guaranteed ELISA serum titer
2 – 5 Clones
Stable single-cell subclones
100% IP
Full commercial ownership & transfer

Precision Monoclonal Antibody Development

SMD Life Sciences offers high-affinity murine monoclonal antibody development designed from the ground up for diagnostic and therapeutic diagnostic applications. Whether you require antibodies for a novel infectious biomarker, a steroid hormone, or a critical cardiac protein, our hybridoma platform delivers stable, high-affinity clones with validated sensitivity and lot-to-lot reproducibility.

Diagnostic Assays (IVD)

High analytical sensitivity and stability across diverse sample matrices (whole blood, serum, plasma, urine).

Matched Pair Screening

Simultaneous validation of capture and detection antibody pairs on colloidal gold rapid test strips and ELISA plates.

Structured Development

4-Phase Milestone Development Architecture

You only pay for milestones as deliverables are verified and approved by your scientific team.

Phase 01

Antigen Preparation & Immunization

⏱️ Weeks 1 – 6
Antigen design, peptide synthesis with KLH carrier coupling, or recombinant antigen validation
Immunization cohort of 5 Balb/c mice using optimized adjuvant formulations
Multi-point booster injections (days 0, 14, 28, and 35)
Serum titer screening via indirect ELISA against target antigen and negative controls
Selection of top 2 high-responding mice for splenic harvest and myeloma fusion
📦 Phase Deliverables:Pre-immune serum, post-booster titration curve, and ELISA titer certificate (>= 1:128,000)
Phase 02

Splenic Fusion & High-Throughput Screening

⏱️ Weeks 7 – 9
Electrofusion / PEG-mediated fusion of splenocytes with Sp2/0-Ag14 non-secreting myeloma cells
Selective HAT (Hypoxanthine-Aminopterin-Thymidine) culture in 96-well microplates
Primary high-throughput screening by indirect ELISA to detect antigen-specific antibodies
Secondary counter-screening against structurally homologous proteins to eliminate cross-reactivity
Functional validation in target application (Sandwich ELISA, Lateral Flow, or Western Blot)
📦 Phase Deliverables:Primary screening data, competitive ELISA inhibition data, and positive fusion master wells
Phase 03

Single-Cell Subcloning & Master Banking

⏱️ Weeks 10 – 12
Serial limiting dilution (2–3 rounds) to establish >99.9% clonal purity
Antibody isotype identification (IgG1, IgG2a, IgG2b, IgM, kappa/lambda light chain)
Subclone stability testing across minimum 30 cellular doublings
Liquid nitrogen cryopreservation: 3 vials per clone deposited into master working cell bank
Comprehensive PCR-based mycoplasma contamination screening
📦 Phase Deliverables:2–5 stable monoclonal hybridoma clones, cryovials stored in liquid nitrogen, mycoplasma certificate
Phase 04

Pilot In-Vitro Production & Protein A/G Purification

⏱️ Weeks 13 – 15
In-vitro suspension culture in serum-free / low-IgG media (roller bottles or bioreactors)
Supernatant clarification and Protein A or Protein G affinity chromatography
Ultrafiltration buffer exchange into sterile 1x PBS (pH 7.4, 0.05% ProClin300 / Azide-free)
Protein quantification via UV A280 (extinction coefficient) and BCA colorimetric assay
Quality testing: Reducing & Non-Reducing SDS-PAGE purity (>95%), Endotoxin testing (<1 EU/mg)
📦 Phase Deliverables:2 to 10 mg purified mAb, SDS-PAGE purity report (>95%), and final project technical dossier
Specialized IVD Capability

Matched Antibody Pair Development for Rapid Tests & ELISA

Unlike academic hybridoma services that deliver antibodies binding random epitopes, we evaluate clones in matrix pairs directly on your chosen detection platform. We identify non-competing epitope pairs where one antibody acts as the solid-phase capture agent (membrane coat) and the second acts as the reporter conjugate (colloidal gold, latex, or fluorescent nanoparticles).

Zero Epitope Overlap

Rigorous competitive cross-blocking assay confirms both antibodies bind simultaneously.

Colloidal Gold Stability

Screening for high conjugation stability at 40nm gold pH 8.0–9.0 without passive precipitation.

Serum Matrix Robustness

Elimination of heterophilic antibody interference and human anti-mouse antibody (HAMA) cross-binding.

Why Choose SMD Life Sciences for Custom mAbs?

Compare our domestic Bangalore facility advantages against overseas vendors and academic labs.

Evaluation ParameterSMD Life SciencesOverseas / Traditional Vendors
Intellectual Property & Clone Ownership100% Client Ownership (Zero reach-through royalties, full commercial freedom)Often retain partial rights or demand licensing fees for commercial diagnostic use
Serum Titer Milestone GuaranteeGuaranteed ELISA titer >= 1:128,000 before proceeding to fusion stageProceed blindly to fusion regardless of immune response quality
IVD Matched Pair Screening CapabilitySimultaneous pairing matrix on Lateral Flow strips and 96-well Sandwich ELISA platesOnly perform standard indirect ELISA, leaving pair optimization to the client
Facility & Cold-Chain LogisticsBangalore Cleanroom Lab & 24–48h dry ice express shipping across IndiaOverseas shipments vulnerable to customs holds, dry ice sublimation, and degradation
Technical Consultation & CustomizationDirect one-on-one scientific milestone review meetings with project immunologistsImpersonal ticketing systems with standard non-negotiable protocols

Frequently Asked Technical Questions

What is the typical turnaround time for custom monoclonal antibody development?

The complete 4-phase hybridoma monoclonal antibody development protocol typically takes 12 to 16 weeks. Fast-track express immunization protocols can yield primary fusion candidates in as early as 9 to 10 weeks.

Who owns the intellectual property (IP) and hybridoma clones?

100% of the intellectual property, parental hybridoma cell lines, sequence data, and generated antibodies belong exclusively to the client. SMD Life Sciences operates on a fee-for-service model with zero reach-through royalties.

Can you develop matched antibody pairs for lateral flow rapid tests and sandwich ELISA?

Yes. We specialize in matched antibody pair development specifically designed for IVD assay platforms. Clones are cross-screened simultaneously as capture antibodies (solid phase) and detection antibodies (colloidal gold/HRP/fluorescent conjugate) to ensure zero epitope competition and high analytical sensitivity.

What happens if the mouse serum titer is insufficient at Phase 1?

We guarantee an ELISA titer of at least 1:128,000 against the target antigen before proceeding to cell fusion. If the titer does not meet benchmark criteria, booster regimens are extended or the project is halted with zero financial liability for subsequent unperformed phases.

Project Inquiry Form

Tell us about your diagnostic or R&D requirements

Fast Evaluation
0 / 1500
NDA protected · Strictly confidential
📍

Bangalore R&D Facility

Electronic City Phase 1, Bangalore

Direct Desk: +91 95554 22455
Email: info@smdmedicare.in
Mutual NDA executed prior to sequence sharing